Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Nov 14, 2024 · CIK: 1581178
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-private-issuer
TL;DR
Eupraxia Pharmaceuticals filed a 6-K with a press release on Nov 14, 2024.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 14, 2024, reporting for the month of November 2024. The filing includes a press release dated November 14, 2024, as Exhibit 99.1. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant financial or operational disclosures that would indicate high risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- November 14, 2024 (date) — Filing date and press release date
- 201-2067 Cadboro Bay Road Victoria, British Columbia, Canada V8R 5G4 (location) — Principal executive office address
- Bruce Cous (person) — Signatory for the filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that are required to furnish information which they have made or are required to make public pursuant to the laws of their home country or a foreign stock exchange or that they have submitted or will submit to their security holders.
What specific document is included as part of this 6-K report?
Exhibit 99.1, a Press Release dated November 14, 2024, is included as part of this report.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
What is the filing date of this Form 6-K?
This Form 6-K was filed on November 14, 2024.
Does Eupraxia Pharmaceuticals file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals files annual reports under Form 40-F.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-11-14 17:00:31
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 15KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001391.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: November 14, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer